Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05351788 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 12, 2026 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Lead sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. to Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Primary completion date: Aug 2024 to Aug 2026 · Completion date: Apr 2026 to Dec 2026v3 Show 2 more changesShow less
    • Primary completion date: Aug 2024 to Aug 2026
    • Completion date: Apr 2026 to Dec 2026
  2. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Aug 2023 to Aug 2024 · Study sites: 1 to 2 · Completion date: Apr 2025 to Apr 2026 · 3 morev2 Show 6 more changesShow less
    • Primary completion date: Aug 2023 to Aug 2024
    • Study sites: 1 to 2
    • Completion date: Apr 2025 to Apr 2026
    • Start date changed from estimate of Apr 2022 to May 20, 2022
    • Secondary endpoints: details revised at 3 of 8 entries
    • Study title shortened, about 7 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB264 in combination with KL-A167 with or without chemotherapy with advanced or metastatic non-small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.
Trial Details
NCT Number NCT05351788
Lead Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions Non-small Cell Lung Cancer
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov